Chemoprevention Considerations in Patients with Hereditary Colorectal Cancer Syndromes

Carole Macaron; Gautam N Mankaney; Mahnur Haider; Mohamad Mouchli; Karen Hurley; Carol A Burke

doi:10.1016/j.giec.2021.08.005

Chemoprevention Considerations in Patients with Hereditary Colorectal Cancer Syndromes

Gastrointest Endosc Clin N Am. 2022 Jan;32(1):131-146. doi: 10.1016/j.giec.2021.08.005.

Authors

Carole Macaron¹, Gautam N Mankaney², Mahnur Haider³, Mohamad Mouchli⁴, Karen Hurley⁵, Carol A Burke⁶

Affiliations

¹ Department of Gastroenterology, Hepatology and Nutrition, Desk A 30, 9500 Euclid Avenue, Cleveland, OH 44195, USA.
² Department of Gastroenterology and Hepatology, Virginia Mason Franciscan Health, 1100 9th Avenue, Seattle, WA 98101, USA.
³ John W. Deming Department of Medicine, Tulane University School of Medicine, 1430 Tulane Avenue, #8016, New Orleans, LA 70112, USA.
⁴ Department of Gastroenterology, Hepatology and Nutrition, Desk A 30, 9500 Euclid Avenue, Cleveland, OH 44195, USA; Department of Gastroenterology, Hepatology, and Nutrition, Digestive Disease and Surgical Institute, Cleveland Clinic, Cleveland, OH, USA.
⁵ Center for Behavioral Health, Desk P57, 9500 Euclid Avenue, Cleveland, OH 44195, USA.
⁶ Department of Gastroenterology, Hepatology and Nutrition, Desk A 30, 9500 Euclid Avenue, Cleveland, OH 44195, USA; Department of Colorectal Surgery, Sanford R. Weiss MD Center for Hereditary Gastrointestinal Neoplasia, Digestive Disease and Surgical Institute, Cleveland Clinic, Cleveland, OH, USA. Electronic address: burkec1@ccf.org.

PMID: 34798982
DOI: 10.1016/j.giec.2021.08.005

Abstract

Secondary prevention of colorectal neoplasia with chemoprevention is long-studied area of research and clinical use in patients with the 2 most common hereditary colorectal cancer syndromes including Lynch syndrome and familial adenomatous polyposis. No medication is currently approved for use for the prevention of colorectal polyps or cancer in either the general population or individuals with the hereditary colorectal cancer syndromes. Emerging data in animal models and limited data in humans suggest vaccines may be the next breakthrough for neoplasia prevention in patients with hereditary colorectal cancer. Clinicians must acknowledge chemoprevention is an adjunct and does not supplant endoscopic surveillance.

Keywords: Chemoprevention; Familial adenomatous polyposis; Hamartomatous polyposis syndromes; Hereditary colon cancer syndromes; Lynch syndrome.

Publication types

Review

MeSH terms

Adenomatous Polyposis Coli* / genetics
Chemoprevention
Colorectal Neoplasms* / genetics
Colorectal Neoplasms* / prevention & control
Colorectal Neoplasms, Hereditary Nonpolyposis* / genetics
Colorectal Neoplasms, Hereditary Nonpolyposis* / prevention & control
Humans
Neoplastic Syndromes, Hereditary*